人多能干细胞衍生的视网膜色素上皮细胞移植治疗黄斑变性

hPSC-derived RPE transplantation for the treatment of macular degeneration.

作者信息

Liu Qian, Liu Jun, Higuchi Akon

机构信息

State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.

State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China; Department of Chemical and Materials Engineering, National Central University, Jhongli, Taoyuan, Taiwan.

出版信息

Prog Mol Biol Transl Sci. 2023;199:227-269. doi: 10.1016/bs.pmbts.2023.02.010. Epub 2023 Mar 14.

DOI:10.1016/bs.pmbts.2023.02.010

PMID:37678973

Abstract

Macular degeneration (MD) is a group of diseases characterized by irreversible and progressive vision loss. Patients with MD suffer from severely impaired central vision, especially elderly people. Currently, only one type of MD, wet age-related macular degeneration (AMD), can be treated with anti-vascular endothelium growth factor (VEGF) drugs. Other types of MD remain difficult to treat. With the advent of human pluripotent stem cells (hPSCs) and their differentiation into retinal pigmented epithelium (RPE), it is promising to treat patients with MD by transplantation of hPSC-derived RPE into the subretinal space. In this review, the current progress in hPSC-derived RPE transplantation for the treatment of patients with MD is described from bench to bedside, including hPSC differentiation into RPE and the characterization and usage of hPSC-derived RPE for transplantation into patients with MD.

摘要

黄斑变性（MD）是一组以不可逆性和进行性视力丧失为特征的疾病。MD患者，尤其是老年人，会遭受严重的中心视力损害。目前，只有一种类型的MD，即湿性年龄相关性黄斑变性（AMD），可以用抗血管内皮生长因子（VEGF）药物治疗。其他类型的MD仍然难以治疗。随着人类多能干细胞（hPSC）的出现及其向视网膜色素上皮（RPE）的分化，通过将hPSC来源的RPE移植到视网膜下间隙来治疗MD患者具有广阔前景。在这篇综述中，将从实验室到临床描述hPSC来源的RPE移植治疗MD患者的当前进展，包括hPSC向RPE的分化以及hPSC来源的RPE用于移植到MD患者中的特性和用途。